Free Trial
NASDAQ:INM

InMed Pharmaceuticals Q4 2024 Earnings Report

InMed Pharmaceuticals logo
$3.02 +0.04 (+1.17%)
Closing price 03:57 PM Eastern
Extended Trading
$3.01 -0.01 (-0.30%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMed Pharmaceuticals EPS Results

Actual EPS
-$3.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

InMed Pharmaceuticals Revenue Results

Actual Revenue
$1.28 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InMed Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
N/A
Conference Call Date
Monday, September 30, 2024
Conference Call Time
6:00AM ET

Upcoming Earnings

InMed Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

InMed Pharmaceuticals Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More InMed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InMed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMed Pharmaceuticals and other key companies, straight to your email.

About InMed Pharmaceuticals

InMed Pharmaceuticals (NASDAQ:INM), a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

View InMed Pharmaceuticals Profile

More Earnings Resources from MarketBeat